Clinical trials: Single Dose
Healthy Adult Male and Female Volunteers
Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants
This study will be conducted to evaluate the relative bioavailability, pharmacokinetics, safety, and tolerability of AVP-923 (dextromethorphan hydrobromide [DM] and quinidine sulfate [Q] capsules) when the contents of a capsule…
- Trial name
- NCT03381664
- Testing
- AVP-923
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Avanir Pharmaceuticals
Healthy
A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fasting Condition
The study was conducted as an open labeled, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing acetaminophen extended release gelcaps 650 mg of OHM Laboratories…
- Trial name
- NCT01073709
- Testing
- Acetaminophen
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ketoconazole
Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects
The purpose of this study is to assess the effect of ketoconazole at steady state on the pharmacokinetics of a single dose of isavuconazole in healthy adult subjects.
- Conditions
- Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ketoconazole, Healthy Adult Volunteers
- Trial name
- NCT01657838
- Testing
- Isavuconazole, Ketoconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy Subjects
First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders
The primary purpose of this first-in-man study is to investigate whether a new drug for neurological disorders is safe and well-tolerated when administered orally to healthy adults
- Trial name
- NCT02702648
- Testing
- AC-082
- Where
- Germany
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00131989
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Spinal Cord Injury
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.
- Trial name
- NCT04096950
- Testing
- MT-3921 Low dose
- Where
- 13 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tanabe Pharma America, Inc.
Healthy
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a…
- Trial name
- NCT02578550
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC), Emtricitabine/tenofovir alafenamide FDC, Darunavir
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
Sickle Cell Disease, Hematological Diseases
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participants with severe sickle cell disease (SCD).
- Conditions
- Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
- Trial name
- NCT03745287
- Testing
- Exa-cel
- Where
- 17 sites in United States, Belgium and 5 more
- Volunteers
- 63 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work…
- Trial name
- NCT00671216
- Testing
- GSK233705, GW642444, GSK233705 and GW642444
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake
The purpose of this study is to determine if, once a favorable dose of TI Inhalation Powder is established for either a type 1 or 2 patient, based on a average diabetic meal, the patient's favorable dose can be used safely…
- Trial name
- NCT00747006
- Testing
- TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mannkind Corporation
Insomnia
A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
To determine the mass balance of PD 0200390
- Trial name
- NCT00722306
- Testing
- PD 0200390
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoporosis
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women
The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single subcutaneous (SC) injection in postmenopausal women
- Trial name
- NCT05930704
- Testing
- SHR-2017 injection
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hepatitis C
A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
GSK2485852 is a Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor being developed for the treatment of chronic HCV infection.
- Trial name
- NCT01332552
- Testing
- GSK2485852 70 mg, GSK2485852 420 mg, GSK2485852 630 mg
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Healthy
Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)
In the present study human recombinant placental alkaline phosphatase (hRESCAP) will be investigated. Alkaline Phosphatase is naturally present in the body and reported to use lipopolysaccharde (LPS, bacterial endotoxins) and…
- Trial name
- NCT01889147
- Testing
- hRESCAP
- Where
- Netherlands
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- TNO
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Venous Leg Ulcer (VLU)
An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers
This is a pharmacokinetics (PK) study - the main objective of this study is to assess the PK, safety and clinical performance of 5% EscharEx (EX-03 formulation) in debridement of Venous Leg Ulcers
- Trial name
- NCT07692178
- Testing
- EX-03
- Volunteers
- 20 people
- Sponsor
- MediWound Ltd
Norovirus Infections
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
- Trial name
- NCT06944717
- Testing
- VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vaxart
Parkinson Disease
Safety, Tolerability and Effects of Mannitol in Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disease that causes disabling motor and cognitive impairments. Currently, no disease-modifying therapy exists for this disease.
- Trial name
- PD-mannitol (NCT03823638)
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Healthy Participants
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3.
- Trial name
- NCT05662215
- Testing
- CK-3828136
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Type2Diabetes
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
- Trial name
- NCT05347576
- Testing
- CKD-393(2), CKD-501, D759, D150, D029
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.